Quantessence Capital’s Madrigal Pharmaceuticals MDGL Stock Holding History

Quantessence Capital’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-658	Closed	-$218K	–	343
2025 Q1	$218K	Buy	+658	New	+$216K	0.05%	270

Other funds holding MDGL

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Quantessence Capital's MDGL Position: Q2 2025 in Review

Quantessence Capital sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2025, closing a stake of 658 shares — an estimated $218K sold.

Quantessence Capital first reported a position in MDGL in Q1 2025 and held it in 1 quarter. The position peaked at $218K in Q1 2025. 305 funds tracked by Wall St. Rank hold MDGL as of Q2 2025.

Quantessence Capital reported no remaining Madrigal Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Quantessence Capital sold 658 Madrigal Pharmaceuticals shares in Q2 2025, an estimated $218K.
Quantessence Capital first reported a position in Madrigal Pharmaceuticals in Q1 2025 and held it in 1 quarter.
Quantessence Capital's Madrigal Pharmaceuticals position peaked at $218K in Q1 2025.
305 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2025.

Based on Quantessence Capital's 13F filing for Q2 2025, filed 14 Aug 2025.